Quantcast
Last updated on April 25, 2014 at 5:25 EDT

Latest Dana-Farber Cancer Institute Stories

2011-09-09 14:22:00

Dana-Farber Cancer Institute scientists have successfully disrupted the function of a cancer gene involved in the formation of most human tumors by tampering with the gene's "on" switch and growth signals, rather than targeting the gene itself. The results, achieved in multiple myeloma cells, offer a promising strategy for treating not only myeloma but also many other cancer types driven by the gene MYC, the study authors say. Their findings are being published by the journal Cell on its...

2011-09-07 19:57:00

Scientists at Dana-Farber Cancer Institute and colleagues overseas have discovered a pair of backup circuits in cancer cells that enable the cells to dodge the effect of a widely used cancer drug. Jamming those circuits with targeted therapies may heighten or restore the drug's potency, according to a study published in the Sept. 7 issue of Science Translational Medicine. The research focused on the drug cetuximab, an antibody that interferes with cancer cell growth by blocking a structure...

2011-09-05 11:23:24

Research offers hope for better treatments for diabetes patients In a joint study, scientists from The Scripps Research Institute and Harvard University's Dana-Farber Cancer Institute have established a new class of anti-diabetic compound that targets a unique molecular switch. The finding paves the way for the development of anti-diabetic therapeutics with minimal adverse side effects plaguing currently available drugs such as Avandia (rosiglitazone), scheduled to be removed from...

2011-08-18 10:00:00

CANTON, Mass., Aug. 18, 2011 /PRNewswire/ -- Dunkin' Donuts is supporting the Dana-Farber Cancer Institute through the Jimmy Fund for the 13th year to help increase the chances of survival among cancer patients worldwide. Dunkin' Donuts and its franchisees maintain an ongoing commitment to the Jimmy Fund, having helped raise a total of $8 million since 1998. This year, Dunkin' Donuts will continue to support the Jimmy Fund and the fight against cancer through several fundraising events and...

2011-08-15 11:00:00

St. Jude Children's Research Hospital scientists lead research that settles a century-old debate about retinoblastoma's beginnings and identify new targets for treating the childhood eye tumor MEMPHIS, Tenn., Aug. 15, 2011 /PRNewswire-USNewswire/ -- A research team led by St. Jude Children's Research Hospital scientists has identified a potential new target for treatment of the childhood eye tumor retinoblastoma. Their work also settles a scientific debate by showing the cancer's...

2011-08-03 15:00:00

SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 3, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) and the Multiple Myeloma Research Foundation (MMRF) today announced the initiation of an expanded access program for carfilzomib, a selective, next-generation proteasome inhibitor. The Carfilzomib Myeloma Access Program (C-MAP) will include eligible patients in the United States (U.S.) with relapsed and refractory multiple myeloma. Expanded access programs make...

c011666b724d316fd6682f5fbce6c79b
2011-07-31 07:22:28

Salk Institute and Dana Farber Cancer Institute researchers contribute to production of largest-ever map of plant protein interactions Science usually progresses in small steps, but on rare occasions, a new combination of research expertise and cutting-edge technology produces a 'great leap forward.' An international team of scientists, whose senior investigators include Salk Institute plant biologist Joseph Ecker, report one such leap in the July 29, 2011 issue of Science. They describe...

2011-07-21 07:45:00

BOSTON, July 21, 2011 /PRNewswire/ -- Zipcar, Inc. (Nasdaq: ZIP), the world's leading car-sharing network, is taking on the 32nd annual Pan-Massachusetts Challenge (PMC) with a team of 25 riders and a goal of raising $150,000 to support cancer research and treatment. This year marks Zipcar's fifth consecutive year of participation in the PMC. Since 2007, Team Zipcar has raised more than $535,000 to benefit adult and pediatric cancer research and treatment at Dana-Farber Cancer Institute....

2011-07-20 17:16:00

Promising results of PI3K inhibitor study discussed at ASCO annual meeting SCOTTSDALE, Ariz., July 20, 2011 /PRNewswire-USNewswire/ -- A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation by oncologist Dr. Daniel D. Von Hoff at the 47th annual meeting of the American Society of Clinical Oncology (ASCO). The drug...

35f3a691ee434334c1248708e09e4147
2011-07-19 13:05:00

Cancer biologists at MIT have identified a new lung cancer gene that drives the spread of the deadly condition. MIT reported that a major challenge for cancer biologists is determining which genetic mutations found in a cancer cell are most important for driving the cancer's spread. The scientists used a new technique called whole-genome profiling to pinpoint the gene that drives progression of small cell lung cancer, which accounts for about 15 percent of lung cancer cases. Alison Dooley,...